{name}
{subtitle}
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
city
~32 mi. (Strasbourg, France, +192 more cities)
facility
Institut de cancérologie Strasbourg Europe (ICANS)
biomarker
ER Positive, +1 more biomarker
drug
abemaciclib, +1 more drug
drug type
hormone therapy, +1 more type
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
city
~32 mi. (Strasbourg, France, +226 more cities)
facility
Clinique Sainte Anne ( Site 0431)
drug
enzalutamide, +1 more drug
drug type
hormone therapy, +1 more type
Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)
city
~32 mi. (Freiburg, Germany, +140 more cities)
facility
Universitaetsklinikum Freiburg ( Site 0199)
drug
lenvatinib, +2 more drugs
drug type
chemotherapy, +2 more types
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
city
~32 mi. (Freiburg, Germany, +93 more cities)
facility
Universitaetsklinikum Freiburg ( Site 0512)
condition
Bladder Carcinoma, +1 more condition
drug
cisplatin, +4 more drugs
drug type
chemotherapy, +3 more types
Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
city
~32 mi. (Strasbourg, France, +199 more cities)
facility
HUS Hopital Hautepierre ( Site 0445)
Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)
city
~32 mi. (Strasbourg, France, +67 more cities)
facility
Nouvel Hôpital Civil (NHC) ( Site 1018)
drug
carboplatin, +5 more drugs
drug type
chemotherapy, +1 more type
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
city
~32 mi. (Strasbourg, France, +105 more cities)
facility
Institut de Cancerologie Strasbourg Europe ( Site 0613)
biomarker
ATM Loss, +62 more biomarkers
condition
Breast Carcinoma, +2 more conditions
Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002)
city
~32 mi. (Strasbourg, France, +76 more cities)
facility
Nouvel Hôpital Civil (NHC) ( Site 1000)
drug
docetaxel, +1 more drug
drug type
chemotherapy, +1 more type